Article Text

Download PDFPDF

EPV183/#227 Parp inhibitors in newly diagnosed advanced ovarian cancer: an assessment of clinical practices
  1. G Fisher1,
  2. A Furedy2,
  3. J Vandenbroucque2 and
  4. J Ledermann3
  1. 1Medscape, Clinical Strategy, London, UK
  2. 2Medscape, Medical Education, London, UK
  3. 3University College London, Ucl Cancer Institute, London, UK


Objectives This study determined the knowledge of clinicians on the evidence for, and application of, PARP inhibitors (PARPi) in newly diagnosed ovarian cancer.

Methods A 27-question, online, continuing medical education (CME) self-assessment was developed that included demographic, knowledge, confidence and practice-based multiple-choice questions. Activity was launched for clinicians practising outside of the USA in July 2020 and data collected to October 2020.

Results 104 oncologists, 46 obstetricians/gynaecologists (obs/gyn) and 21 other physicians completed the assessment. Participants were divided evenly between academic and community practice, but only 20% specialized in ovarian cancer. Only 33% were moderately/very confident (across a 5-point Likert scale) in their ability to select an appropriate PARPi maintenance regimen. Knowledge of key trials was low. 56% identified the population of the SOLO 1 trial, 37% patient characteristics, 29% correct PFS outcome and 43% most common AEs. 56% identified the outcome of the PRIMA trial, 33% patient characteristics, 28% efficacy in key subpopulations, and 43% most common G3/4 AEs. 49% identified the outcome of the PAOLA-1 trial, 44% efficacy in key subpopulations, and 44% the AE profile. Only 32% identified the appropriate PARPi maintenance regimen for a patient with HRD-ve/BRCA-ve disease following carboplatin/paclitaxel, whilst 77% identified the appropriate PARPi maintenance strategy following chemotherapy + bevacizumab for BRCA+ve disease. Obs/gyns and other physicians generally performed worse than oncologists in terms of knowledge and confidence.

Conclusions The knowledge and confidence gaps revealed indicate there is a significant need for education to facilitate optimal application of PARPi maintenance strategies in newly diagnosed ovarian cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.